nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—MKNK2—Gefitinib—lung cancer	0.0623	0.0908	CbGbCtD
Ruxolitinib—ANKK1—Crizotinib—lung cancer	0.0528	0.077	CbGbCtD
Ruxolitinib—DCLK1—Crizotinib—lung cancer	0.0528	0.077	CbGbCtD
Ruxolitinib—TAOK2—Crizotinib—lung cancer	0.0382	0.0557	CbGbCtD
Ruxolitinib—TYK2—Crizotinib—lung cancer	0.0382	0.0557	CbGbCtD
Ruxolitinib—JAK3—Crizotinib—lung cancer	0.0382	0.0557	CbGbCtD
Ruxolitinib—JAK3—Erlotinib—lung cancer	0.0368	0.0537	CbGbCtD
Ruxolitinib—IRAK1—Gefitinib—lung cancer	0.0358	0.0522	CbGbCtD
Ruxolitinib—JAK2—Crizotinib—lung cancer	0.0303	0.0442	CbGbCtD
Ruxolitinib—LTK—Crizotinib—lung cancer	0.0303	0.0442	CbGbCtD
Ruxolitinib—NUAK2—Crizotinib—lung cancer	0.0303	0.0442	CbGbCtD
Ruxolitinib—BMP2K—Crizotinib—lung cancer	0.0303	0.0442	CbGbCtD
Ruxolitinib—LTK—Erlotinib—lung cancer	0.0293	0.0427	CbGbCtD
Ruxolitinib—PLK4—Crizotinib—lung cancer	0.0254	0.037	CbGbCtD
Ruxolitinib—TAOK3—Crizotinib—lung cancer	0.0254	0.037	CbGbCtD
Ruxolitinib—MAP3K3—Crizotinib—lung cancer	0.0254	0.037	CbGbCtD
Ruxolitinib—MAP3K19—Gefitinib—lung cancer	0.0238	0.0347	CbGbCtD
Ruxolitinib—IRAK1—Crizotinib—lung cancer	0.0219	0.032	CbGbCtD
Ruxolitinib—MAP3K2—Crizotinib—lung cancer	0.0219	0.032	CbGbCtD
Ruxolitinib—MAP3K19—Crizotinib—lung cancer	0.0146	0.0212	CbGbCtD
Ruxolitinib—MAP3K19—Erlotinib—lung cancer	0.0141	0.0205	CbGbCtD
Ruxolitinib—BMPR2—pulmonary artery—lung cancer	0.004	0.0523	CbGeAlD
Ruxolitinib—PLK1—respiratory system—lung cancer	0.00126	0.0164	CbGeAlD
Ruxolitinib—DAPK2—mammary gland—lung cancer	0.00115	0.015	CbGeAlD
Ruxolitinib—HIPK2—mammary gland—lung cancer	0.00113	0.0147	CbGeAlD
Ruxolitinib—CYP3A4—Topotecan—lung cancer	0.00111	0.00162	CbGbCtD
Ruxolitinib—DAPK3—mammary gland—lung cancer	0.00108	0.0141	CbGeAlD
Ruxolitinib—CYP3A4—Gefitinib—lung cancer	0.00101	0.00148	CbGbCtD
Ruxolitinib—DYRK1A—mammary gland—lung cancer	0.00101	0.0132	CbGeAlD
Ruxolitinib—BMPR2—mammary gland—lung cancer	0.00101	0.0132	CbGeAlD
Ruxolitinib—CYP3A4—Teniposide—lung cancer	0.000983	0.00143	CbGbCtD
Ruxolitinib—ROCK1—Irinotecan—Topotecan—lung cancer	0.000871	0.257	CbGdCrCtD
Ruxolitinib—PLK3—bronchus—lung cancer	0.000863	0.0113	CbGeAlD
Ruxolitinib—MAP3K7—mammary gland—lung cancer	0.000813	0.0106	CbGeAlD
Ruxolitinib—JAK1—respiratory system—lung cancer	0.000804	0.0105	CbGeAlD
Ruxolitinib—PLK4—respiratory system—lung cancer	0.000799	0.0104	CbGeAlD
Ruxolitinib—MKNK2—mammary gland—lung cancer	0.000788	0.0103	CbGeAlD
Ruxolitinib—CAMK1D—respiratory system—lung cancer	0.000785	0.0103	CbGeAlD
Ruxolitinib—CYP3A4—Vinorelbine—lung cancer	0.000781	0.00114	CbGbCtD
Ruxolitinib—PLK3—trachea—lung cancer	0.000775	0.0101	CbGeAlD
Ruxolitinib—RET—mammary gland—lung cancer	0.000768	0.01	CbGeAlD
Ruxolitinib—HIPK2—respiratory system—lung cancer	0.000751	0.00981	CbGeAlD
Ruxolitinib—PRKG2—lung—lung cancer	0.000743	0.00971	CbGeAlD
Ruxolitinib—MAP3K19—respiratory system—lung cancer	0.000735	0.00961	CbGeAlD
Ruxolitinib—PLK3—cardiac atrium—lung cancer	0.000728	0.00951	CbGeAlD
Ruxolitinib—JAK2—mammary gland—lung cancer	0.000726	0.00949	CbGeAlD
Ruxolitinib—CLK2—respiratory system—lung cancer	0.000715	0.00934	CbGeAlD
Ruxolitinib—MAP3K3—mammary gland—lung cancer	0.0007	0.00914	CbGeAlD
Ruxolitinib—PRKCE—lung—lung cancer	0.000694	0.00907	CbGeAlD
Ruxolitinib—ROCK1—respiratory system—lung cancer	0.000693	0.00905	CbGeAlD
Ruxolitinib—DYRK1A—respiratory system—lung cancer	0.000675	0.00883	CbGeAlD
Ruxolitinib—BMPR2—respiratory system—lung cancer	0.000673	0.00879	CbGeAlD
Ruxolitinib—JAK1—epithelium—lung cancer	0.000672	0.00878	CbGeAlD
Ruxolitinib—PLK1—lung—lung cancer	0.000667	0.00871	CbGeAlD
Ruxolitinib—RPS6KA6—lung—lung cancer	0.000667	0.00871	CbGeAlD
Ruxolitinib—JAK1—bronchus—lung cancer	0.000662	0.00865	CbGeAlD
Ruxolitinib—CAMK1D—bronchus—lung cancer	0.000646	0.00844	CbGeAlD
Ruxolitinib—DAPK2—bronchus—lung cancer	0.000631	0.00825	CbGeAlD
Ruxolitinib—CYP3A4—Crizotinib—lung cancer	0.000621	0.000906	CbGbCtD
Ruxolitinib—CAMK2G—respiratory system—lung cancer	0.000602	0.00787	CbGeAlD
Ruxolitinib—CYP3A4—Erlotinib—lung cancer	0.0006	0.000874	CbGbCtD
Ruxolitinib—LRRK2—respiratory system—lung cancer	0.000597	0.0078	CbGeAlD
Ruxolitinib—JAK1—trachea—lung cancer	0.000594	0.00777	CbGeAlD
Ruxolitinib—DCLK1—trachea—lung cancer	0.000594	0.00777	CbGeAlD
Ruxolitinib—DAPK3—bronchus—lung cancer	0.000594	0.00776	CbGeAlD
Ruxolitinib—CLK2—bronchus—lung cancer	0.000588	0.00768	CbGeAlD
Ruxolitinib—CAMK1D—trachea—lung cancer	0.00058	0.00758	CbGeAlD
Ruxolitinib—ROCK1—epithelium—lung cancer	0.000579	0.00756	CbGeAlD
Ruxolitinib—DAPK2—trachea—lung cancer	0.000567	0.00741	CbGeAlD
Ruxolitinib—JAK1—cardiac atrium—lung cancer	0.000558	0.00729	CbGeAlD
Ruxolitinib—PLK3—lung—lung cancer	0.000557	0.00727	CbGeAlD
Ruxolitinib—BMPR2—bronchus—lung cancer	0.000554	0.00723	CbGeAlD
Ruxolitinib—CYP3A4—Paclitaxel—lung cancer	0.000549	0.0008	CbGbCtD
Ruxolitinib—CAMK1D—cardiac atrium—lung cancer	0.000545	0.00712	CbGeAlD
Ruxolitinib—CYP3A4—Irinotecan—lung cancer	0.000541	0.000789	CbGbCtD
Ruxolitinib—LTK—lung—lung cancer	0.000537	0.00702	CbGeAlD
Ruxolitinib—DAPK2—cardiac atrium—lung cancer	0.000533	0.00696	CbGeAlD
Ruxolitinib—TYK2—respiratory system—lung cancer	0.000532	0.00695	CbGeAlD
Ruxolitinib—CLK2—trachea—lung cancer	0.000528	0.0069	CbGeAlD
Ruxolitinib—MKNK2—respiratory system—lung cancer	0.000525	0.00686	CbGeAlD
Ruxolitinib—CAMK1—lung—lung cancer	0.000521	0.0068	CbGeAlD
Ruxolitinib—MARK2—lung—lung cancer	0.000505	0.0066	CbGeAlD
Ruxolitinib—DAPK3—cardiac atrium—lung cancer	0.000501	0.00654	CbGeAlD
Ruxolitinib—CLK2—cardiac atrium—lung cancer	0.000496	0.00648	CbGeAlD
Ruxolitinib—BMP2K—bronchus—lung cancer	0.000495	0.00647	CbGeAlD
Ruxolitinib—JAK2—respiratory system—lung cancer	0.000484	0.00632	CbGeAlD
Ruxolitinib—CYP3A4—Vinblastine—lung cancer	0.000481	0.000702	CbGbCtD
Ruxolitinib—NUAK2—trachea—lung cancer	0.000475	0.00621	CbGeAlD
Ruxolitinib—PRKCE—lymph node—lung cancer	0.000475	0.0062	CbGeAlD
Ruxolitinib—JAK1—bone marrow—lung cancer	0.000471	0.00616	CbGeAlD
Ruxolitinib—PLK4—bone marrow—lung cancer	0.000468	0.00612	CbGeAlD
Ruxolitinib—TAOK2—lung—lung cancer	0.000468	0.00611	CbGeAlD
Ruxolitinib—BMPR2—cardiac atrium—lung cancer	0.000467	0.0061	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—lung cancer	0.000456	0.00596	CbGeAlD
Ruxolitinib—PLK1—lymph node—lung cancer	0.000456	0.00596	CbGeAlD
Ruxolitinib—DAPK2—bone marrow—lung cancer	0.00045	0.00588	CbGeAlD
Ruxolitinib—MAP3K7—bronchus—lung cancer	0.000446	0.00582	CbGeAlD
Ruxolitinib—MKNK2—epithelium—lung cancer	0.000439	0.00573	CbGeAlD
Ruxolitinib—TYK2—bronchus—lung cancer	0.000438	0.00572	CbGeAlD
Ruxolitinib—CYP3A4—Etoposide—lung cancer	0.000434	0.000632	CbGbCtD
Ruxolitinib—MKNK2—bronchus—lung cancer	0.000432	0.00564	CbGeAlD
Ruxolitinib—IRAK1—bronchus—lung cancer	0.000432	0.00564	CbGeAlD
Ruxolitinib—JAK3—lung—lung cancer	0.00043	0.00562	CbGeAlD
Ruxolitinib—RET—epithelium—lung cancer	0.000428	0.00559	CbGeAlD
Ruxolitinib—JAK1—lung—lung cancer	0.000427	0.00558	CbGeAlD
Ruxolitinib—DCLK1—lung—lung cancer	0.000427	0.00558	CbGeAlD
Ruxolitinib—TAOK3—respiratory system—lung cancer	0.000425	0.00556	CbGeAlD
Ruxolitinib—PLK4—lung—lung cancer	0.000424	0.00555	CbGeAlD
Ruxolitinib—CLK2—bone marrow—lung cancer	0.000419	0.00547	CbGeAlD
Ruxolitinib—CAMK1D—lung—lung cancer	0.000417	0.00545	CbGeAlD
Ruxolitinib—PHKG2—lung—lung cancer	0.000414	0.00541	CbGeAlD
Ruxolitinib—DAPK2—lung—lung cancer	0.000407	0.00532	CbGeAlD
Ruxolitinib—JAK2—epithelium—lung cancer	0.000404	0.00528	CbGeAlD
Ruxolitinib—STK16—lung—lung cancer	0.000401	0.00524	CbGeAlD
Ruxolitinib—MAP3K7—trachea—lung cancer	0.0004	0.00523	CbGeAlD
Ruxolitinib—HIPK2—lung—lung cancer	0.000399	0.00521	CbGeAlD
Ruxolitinib—JAK2—bronchus—lung cancer	0.000398	0.0052	CbGeAlD
Ruxolitinib—CYP3A4—Docetaxel—lung cancer	0.000397	0.000579	CbGbCtD
Ruxolitinib—TYK2—trachea—lung cancer	0.000393	0.00514	CbGeAlD
Ruxolitinib—MAP3K19—lung—lung cancer	0.000391	0.0051	CbGeAlD
Ruxolitinib—MKNK2—trachea—lung cancer	0.000388	0.00507	CbGeAlD
Ruxolitinib—MAP3K3—bronchus—lung cancer	0.000384	0.00501	CbGeAlD
Ruxolitinib—DAPK3—lung—lung cancer	0.000383	0.005	CbGeAlD
Ruxolitinib—PLK3—lymph node—lung cancer	0.000381	0.00497	CbGeAlD
Ruxolitinib—CLK2—lung—lung cancer	0.000379	0.00496	CbGeAlD
Ruxolitinib—NUAK2—bone marrow—lung cancer	0.000377	0.00492	CbGeAlD
Ruxolitinib—MAP3K7—cardiac atrium—lung cancer	0.000376	0.00491	CbGeAlD
Ruxolitinib—TYK2—cardiac atrium—lung cancer	0.000369	0.00482	CbGeAlD
Ruxolitinib—ROCK1—lung—lung cancer	0.000368	0.00481	CbGeAlD
Ruxolitinib—LTK—lymph node—lung cancer	0.000368	0.0048	CbGeAlD
Ruxolitinib—MKNK2—cardiac atrium—lung cancer	0.000364	0.00476	CbGeAlD
Ruxolitinib—DYRK1A—lung—lung cancer	0.000359	0.00469	CbGeAlD
Ruxolitinib—JAK2—trachea—lung cancer	0.000358	0.00467	CbGeAlD
Ruxolitinib—BMPR2—lung—lung cancer	0.000357	0.00467	CbGeAlD
Ruxolitinib—CAMK1—lymph node—lung cancer	0.000356	0.00465	CbGeAlD
Ruxolitinib—CAMK2G—bone marrow—lung cancer	0.000353	0.00461	CbGeAlD
Ruxolitinib—BMP2K—bone marrow—lung cancer	0.000353	0.00461	CbGeAlD
Ruxolitinib—TAOK3—bronchus—lung cancer	0.00035	0.00457	CbGeAlD
Ruxolitinib—LRRK2—bone marrow—lung cancer	0.00035	0.00457	CbGeAlD
Ruxolitinib—MARK2—lymph node—lung cancer	0.000346	0.00452	CbGeAlD
Ruxolitinib—MAP3K3—trachea—lung cancer	0.000345	0.0045	CbGeAlD
Ruxolitinib—NUAK2—lung—lung cancer	0.000341	0.00446	CbGeAlD
Ruxolitinib—JAK2—cardiac atrium—lung cancer	0.000336	0.00439	CbGeAlD
Ruxolitinib—MAP3K3—cardiac atrium—lung cancer	0.000324	0.00423	CbGeAlD
Ruxolitinib—MAP3K2—bone marrow—lung cancer	0.00032	0.00419	CbGeAlD
Ruxolitinib—TAOK2—lymph node—lung cancer	0.00032	0.00418	CbGeAlD
Ruxolitinib—BMP2K—lung—lung cancer	0.00032	0.00418	CbGeAlD
Ruxolitinib—CAMK2G—lung—lung cancer	0.00032	0.00418	CbGeAlD
Ruxolitinib—MAP3K7—bone marrow—lung cancer	0.000317	0.00415	CbGeAlD
Ruxolitinib—LRRK2—lung—lung cancer	0.000317	0.00414	CbGeAlD
Ruxolitinib—TAOK3—trachea—lung cancer	0.000314	0.00411	CbGeAlD
Ruxolitinib—TYK2—bone marrow—lung cancer	0.000312	0.00407	CbGeAlD
Ruxolitinib—IRAK1—bone marrow—lung cancer	0.000308	0.00402	CbGeAlD
Ruxolitinib—MKNK2—bone marrow—lung cancer	0.000308	0.00402	CbGeAlD
Ruxolitinib—DYRK1A—Topotecan—Irinotecan—lung cancer	0.000301	0.0887	CbGdCrCtD
Ruxolitinib—CYP3A4—Doxorubicin—lung cancer	0.000296	0.000431	CbGbCtD
Ruxolitinib—Gastrointestinal disorder—Gefitinib—lung cancer	0.000295	0.00372	CcSEcCtD
Ruxolitinib—TAOK3—cardiac atrium—lung cancer	0.000295	0.00386	CbGeAlD
Ruxolitinib—Pancytopenia—Vinorelbine—lung cancer	0.000295	0.00372	CcSEcCtD
Ruxolitinib—Bone pain—Docetaxel—lung cancer	0.000295	0.00371	CcSEcCtD
Ruxolitinib—Fatigue—Gefitinib—lung cancer	0.000295	0.00371	CcSEcCtD
Ruxolitinib—JAK3—lymph node—lung cancer	0.000294	0.00384	CbGeAlD
Ruxolitinib—Haemoglobin—Topotecan—lung cancer	0.000292	0.00368	CcSEcCtD
Ruxolitinib—JAK1—lymph node—lung cancer	0.000292	0.00382	CbGeAlD
Ruxolitinib—DCLK1—lymph node—lung cancer	0.000292	0.00382	CbGeAlD
Ruxolitinib—Haemorrhage—Topotecan—lung cancer	0.000291	0.00366	CcSEcCtD
Ruxolitinib—Neutropenia—Vinorelbine—lung cancer	0.000291	0.00366	CcSEcCtD
Ruxolitinib—MAP3K2—lung—lung cancer	0.00029	0.00379	CbGeAlD
Ruxolitinib—PLK4—lymph node—lung cancer	0.00029	0.00379	CbGeAlD
Ruxolitinib—Haemoglobin—Erlotinib—lung cancer	0.000289	0.00364	CcSEcCtD
Ruxolitinib—Haemorrhage—Erlotinib—lung cancer	0.000288	0.00362	CcSEcCtD
Ruxolitinib—MAP3K7—lung—lung cancer	0.000288	0.00376	CbGeAlD
Ruxolitinib—CAMK1D—lymph node—lung cancer	0.000285	0.00372	CbGeAlD
Ruxolitinib—JAK2—bone marrow—lung cancer	0.000284	0.00371	CbGeAlD
Ruxolitinib—PHKG2—lymph node—lung cancer	0.000283	0.0037	CbGeAlD
Ruxolitinib—TYK2—lung—lung cancer	0.000282	0.00369	CbGeAlD
Ruxolitinib—Weight decreased—Vinorelbine—lung cancer	0.000281	0.00354	CcSEcCtD
Ruxolitinib—MKNK2—lung—lung cancer	0.000279	0.00364	CbGeAlD
Ruxolitinib—IRAK1—lung—lung cancer	0.000279	0.00364	CbGeAlD
Ruxolitinib—DAPK2—lymph node—lung cancer	0.000279	0.00364	CbGeAlD
Ruxolitinib—Infestation NOS—Vinorelbine—lung cancer	0.000277	0.00349	CcSEcCtD
Ruxolitinib—Infestation—Vinorelbine—lung cancer	0.000277	0.00349	CcSEcCtD
Ruxolitinib—Infection—Teniposide—lung cancer	0.000277	0.00349	CcSEcCtD
Ruxolitinib—STK16—lymph node—lung cancer	0.000274	0.00358	CbGeAlD
Ruxolitinib—MAP3K3—bone marrow—lung cancer	0.000273	0.00357	CbGeAlD
Ruxolitinib—Thrombocytopenia—Teniposide—lung cancer	0.000273	0.00344	CcSEcCtD
Ruxolitinib—HIPK2—lymph node—lung cancer	0.000273	0.00356	CbGeAlD
Ruxolitinib—Body temperature increased—Pemetrexed—lung cancer	0.000272	0.00343	CcSEcCtD
Ruxolitinib—Herpes zoster—Methotrexate—lung cancer	0.00027	0.00341	CcSEcCtD
Ruxolitinib—Body temperature increased—Gefitinib—lung cancer	0.00027	0.00341	CcSEcCtD
Ruxolitinib—Asthenia—Crizotinib—lung cancer	0.00027	0.0034	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Cisplatin—lung cancer	0.000269	0.00339	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Vinorelbine—lung cancer	0.000262	0.0033	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—lung cancer	0.000262	0.00342	CbGeAlD
Ruxolitinib—CLK2—lymph node—lung cancer	0.000259	0.00339	CbGeAlD
Ruxolitinib—JAK2—lung—lung cancer	0.000257	0.00336	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Gemcitabine—lung cancer	0.000255	0.00321	CcSEcCtD
Ruxolitinib—Malnutrition—Topotecan—lung cancer	0.000253	0.00319	CcSEcCtD
Ruxolitinib—Malnutrition—Erlotinib—lung cancer	0.00025	0.00316	CcSEcCtD
Ruxolitinib—TAOK3—bone marrow—lung cancer	0.000249	0.00326	CbGeAlD
Ruxolitinib—Dizziness—Crizotinib—lung cancer	0.000249	0.00314	CcSEcCtD
Ruxolitinib—MAP3K3—lung—lung cancer	0.000248	0.00324	CbGeAlD
Ruxolitinib—PLK1—Irinotecan—Topotecan—lung cancer	0.000247	0.0729	CbGdCrCtD
Ruxolitinib—Asthenia—Pemetrexed—lung cancer	0.000247	0.00311	CcSEcCtD
Ruxolitinib—Flatulence—Erlotinib—lung cancer	0.000247	0.00311	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—lung cancer	0.000245	0.00321	CbGeAlD
Ruxolitinib—Asthenia—Gefitinib—lung cancer	0.000245	0.00309	CcSEcCtD
Ruxolitinib—BMPR2—lymph node—lung cancer	0.000244	0.00319	CbGeAlD
Ruxolitinib—Pruritus—Pemetrexed—lung cancer	0.000243	0.00307	CcSEcCtD
Ruxolitinib—Pruritus—Gefitinib—lung cancer	0.000242	0.00305	CcSEcCtD
Ruxolitinib—Anaemia—Vinblastine—lung cancer	0.000241	0.00303	CcSEcCtD
Ruxolitinib—Neutropenia—Irinotecan—lung cancer	0.00024	0.00302	CcSEcCtD
Ruxolitinib—Pancytopenia—Gemcitabine—lung cancer	0.000237	0.00299	CcSEcCtD
Ruxolitinib—Herpes zoster—Doxorubicin—lung cancer	0.000234	0.00295	CcSEcCtD
Ruxolitinib—Anaemia—Topotecan—lung cancer	0.000234	0.00295	CcSEcCtD
Ruxolitinib—NUAK2—lymph node—lung cancer	0.000233	0.00305	CbGeAlD
Ruxolitinib—Neutropenia—Gemcitabine—lung cancer	0.000233	0.00294	CcSEcCtD
Ruxolitinib—Weight decreased—Irinotecan—lung cancer	0.000232	0.00292	CcSEcCtD
Ruxolitinib—Dizziness—Pemetrexed—lung cancer	0.000228	0.00287	CcSEcCtD
Ruxolitinib—TAOK3—lung—lung cancer	0.000226	0.00295	CbGeAlD
Ruxolitinib—Pancytopenia—Cisplatin—lung cancer	0.000221	0.00278	CcSEcCtD
Ruxolitinib—Body temperature increased—Teniposide—lung cancer	0.00022	0.00278	CcSEcCtD
Ruxolitinib—BMP2K—lymph node—lung cancer	0.000219	0.00286	CbGeAlD
Ruxolitinib—CAMK2G—lymph node—lung cancer	0.000219	0.00286	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Etoposide—lung cancer	0.000218	0.00274	CcSEcCtD
Ruxolitinib—LRRK2—lymph node—lung cancer	0.000217	0.00283	CbGeAlD
Ruxolitinib—Malnutrition—Vinorelbine—lung cancer	0.000216	0.00273	CcSEcCtD
Ruxolitinib—PLK1—Erlotinib—Gefitinib—lung cancer	0.000216	0.0636	CbGdCrCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—lung cancer	0.000214	0.0027	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Paclitaxel—lung cancer	0.000213	0.00269	CcSEcCtD
Ruxolitinib—Haematuria—Gemcitabine—lung cancer	0.000212	0.00267	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—lung cancer	0.000212	0.00267	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Gemcitabine—lung cancer	0.00021	0.00265	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vinblastine—lung cancer	0.000208	0.00262	CcSEcCtD
Ruxolitinib—Haemoglobin—Irinotecan—lung cancer	0.000206	0.0026	CcSEcCtD
Ruxolitinib—PLK4—Topotecan—Irinotecan—lung cancer	0.000205	0.0606	CbGdCrCtD
Ruxolitinib—PLK1—Topotecan—Irinotecan—lung cancer	0.000205	0.0606	CbGdCrCtD
Ruxolitinib—Infection—Topotecan—lung cancer	0.000205	0.00259	CcSEcCtD
Ruxolitinib—Haemorrhage—Irinotecan—lung cancer	0.000205	0.00258	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Docetaxel—lung cancer	0.000205	0.00258	CcSEcCtD
Ruxolitinib—PLK1—Etoposide—Teniposide—lung cancer	0.000204	0.0602	CbGdCrCtD
Ruxolitinib—PLK4—Etoposide—Teniposide—lung cancer	0.000204	0.0602	CbGdCrCtD
Ruxolitinib—Infection—Erlotinib—lung cancer	0.000203	0.00256	CcSEcCtD
Ruxolitinib—Nervous system disorder—Topotecan—lung cancer	0.000203	0.00255	CcSEcCtD
Ruxolitinib—Pancytopenia—Etoposide—lung cancer	0.000202	0.00255	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Topotecan—lung cancer	0.000202	0.00255	CcSEcCtD
Ruxolitinib—Haemoglobin—Gemcitabine—lung cancer	0.000201	0.00253	CcSEcCtD
Ruxolitinib—Skin disorder—Topotecan—lung cancer	0.000201	0.00253	CcSEcCtD
Ruxolitinib—Nervous system disorder—Erlotinib—lung cancer	0.0002	0.00253	CcSEcCtD
Ruxolitinib—Anaemia—Vinorelbine—lung cancer	0.0002	0.00252	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Erlotinib—lung cancer	0.0002	0.00252	CcSEcCtD
Ruxolitinib—Asthenia—Teniposide—lung cancer	0.0002	0.00252	CcSEcCtD
Ruxolitinib—Haemorrhage—Gemcitabine—lung cancer	0.0002	0.00252	CcSEcCtD
Ruxolitinib—Neutropenia—Etoposide—lung cancer	0.000199	0.00251	CcSEcCtD
Ruxolitinib—MAP3K2—lymph node—lung cancer	0.000199	0.00259	CbGeAlD
Ruxolitinib—Skin disorder—Erlotinib—lung cancer	0.000198	0.0025	CcSEcCtD
Ruxolitinib—Pancytopenia—Paclitaxel—lung cancer	0.000198	0.0025	CcSEcCtD
Ruxolitinib—Pruritus—Teniposide—lung cancer	0.000197	0.00248	CcSEcCtD
Ruxolitinib—MAP3K7—lymph node—lung cancer	0.000197	0.00257	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Cisplatin—lung cancer	0.000196	0.00247	CcSEcCtD
Ruxolitinib—Neutropenia—Paclitaxel—lung cancer	0.000195	0.00246	CcSEcCtD
Ruxolitinib—TYK2—lymph node—lung cancer	0.000193	0.00252	CbGeAlD
Ruxolitinib—MKNK2—lymph node—lung cancer	0.000191	0.00249	CbGeAlD
Ruxolitinib—IRAK1—lymph node—lung cancer	0.000191	0.00249	CbGeAlD
Ruxolitinib—Weight increased—Paclitaxel—lung cancer	0.00019	0.0024	CcSEcCtD
Ruxolitinib—Infestation—Etoposide—lung cancer	0.00019	0.00239	CcSEcCtD
Ruxolitinib—Infestation NOS—Etoposide—lung cancer	0.00019	0.00239	CcSEcCtD
Ruxolitinib—Weight decreased—Paclitaxel—lung cancer	0.000189	0.00238	CcSEcCtD
Ruxolitinib—Infestation NOS—Paclitaxel—lung cancer	0.000186	0.00235	CcSEcCtD
Ruxolitinib—Infestation—Paclitaxel—lung cancer	0.000186	0.00235	CcSEcCtD
Ruxolitinib—RET—lymph node—lung cancer	0.000186	0.00243	CbGeAlD
Ruxolitinib—Bone pain—Doxorubicin—lung cancer	0.000184	0.00232	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Vinorelbine—lung cancer	0.000183	0.00231	CcSEcCtD
Ruxolitinib—Urinary tract infection—Paclitaxel—lung cancer	0.000181	0.00228	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Docetaxel—lung cancer	0.000181	0.00228	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Etoposide—lung cancer	0.00018	0.00226	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Topotecan—lung cancer	0.000178	0.00225	CcSEcCtD
Ruxolitinib—Fatigue—Topotecan—lung cancer	0.000178	0.00224	CcSEcCtD
Ruxolitinib—Haematuria—Paclitaxel—lung cancer	0.000178	0.00224	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Erlotinib—lung cancer	0.000176	0.00222	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Paclitaxel—lung cancer	0.000176	0.00222	CcSEcCtD
Ruxolitinib—Fatigue—Erlotinib—lung cancer	0.000176	0.00222	CcSEcCtD
Ruxolitinib—Flatulence—Irinotecan—lung cancer	0.000176	0.00222	CcSEcCtD
Ruxolitinib—Epistaxis—Paclitaxel—lung cancer	0.000176	0.00221	CcSEcCtD
Ruxolitinib—JAK2—lymph node—lung cancer	0.000176	0.0023	CbGeAlD
Ruxolitinib—Infection—Vinorelbine—lung cancer	0.000176	0.00221	CcSEcCtD
Ruxolitinib—Headache—Teniposide—lung cancer	0.000175	0.0022	CcSEcCtD
Ruxolitinib—Nervous system disorder—Vinorelbine—lung cancer	0.000173	0.00218	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Vinorelbine—lung cancer	0.000173	0.00218	CcSEcCtD
Ruxolitinib—Skin disorder—Vinorelbine—lung cancer	0.000172	0.00216	CcSEcCtD
Ruxolitinib—MAP3K3—lymph node—lung cancer	0.000169	0.00221	CbGeAlD
Ruxolitinib—Pancytopenia—Docetaxel—lung cancer	0.000168	0.00212	CcSEcCtD
Ruxolitinib—Haemoglobin—Paclitaxel—lung cancer	0.000168	0.00212	CcSEcCtD
Ruxolitinib—Haemorrhage—Paclitaxel—lung cancer	0.000167	0.00211	CcSEcCtD
Ruxolitinib—Neutropenia—Docetaxel—lung cancer	0.000166	0.00209	CcSEcCtD
Ruxolitinib—Anaemia—Irinotecan—lung cancer	0.000165	0.00208	CcSEcCtD
Ruxolitinib—Body temperature increased—Topotecan—lung cancer	0.000163	0.00206	CcSEcCtD
Ruxolitinib—Malnutrition—Cisplatin—lung cancer	0.000162	0.00204	CcSEcCtD
Ruxolitinib—Body temperature increased—Erlotinib—lung cancer	0.000162	0.00204	CcSEcCtD
Ruxolitinib—Weight increased—Docetaxel—lung cancer	0.000161	0.00203	CcSEcCtD
Ruxolitinib—Anaemia—Gemcitabine—lung cancer	0.000161	0.00203	CcSEcCtD
Ruxolitinib—Weight decreased—Docetaxel—lung cancer	0.00016	0.00202	CcSEcCtD
Ruxolitinib—Flatulence—Cisplatin—lung cancer	0.00016	0.00201	CcSEcCtD
Ruxolitinib—Infestation NOS—Docetaxel—lung cancer	0.000158	0.00199	CcSEcCtD
Ruxolitinib—Infestation—Docetaxel—lung cancer	0.000158	0.00199	CcSEcCtD
Ruxolitinib—TAOK3—lymph node—lung cancer	0.000154	0.00202	CbGeAlD
Ruxolitinib—Asthenia—Vinblastine—lung cancer	0.000153	0.00192	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Vinorelbine—lung cancer	0.000153	0.00192	CcSEcCtD
Ruxolitinib—Fatigue—Vinorelbine—lung cancer	0.000152	0.00192	CcSEcCtD
Ruxolitinib—Anaemia—Cisplatin—lung cancer	0.00015	0.00189	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Docetaxel—lung cancer	0.000149	0.00188	CcSEcCtD
Ruxolitinib—Epistaxis—Docetaxel—lung cancer	0.000149	0.00188	CcSEcCtD
Ruxolitinib—Asthenia—Topotecan—lung cancer	0.000148	0.00187	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—lung cancer	0.000147	0.00185	CcSEcCtD
Ruxolitinib—Asthenia—Erlotinib—lung cancer	0.000147	0.00185	CcSEcCtD
Ruxolitinib—PLK1—Methotrexate—Pemetrexed—lung cancer	0.000146	0.0432	CbGdCrCtD
Ruxolitinib—Pruritus—Topotecan—lung cancer	0.000146	0.00184	CcSEcCtD
Ruxolitinib—Malnutrition—Paclitaxel—lung cancer	0.000146	0.00183	CcSEcCtD
Ruxolitinib—Infection—Irinotecan—lung cancer	0.000145	0.00182	CcSEcCtD
Ruxolitinib—Pruritus—Erlotinib—lung cancer	0.000145	0.00182	CcSEcCtD
Ruxolitinib—Flatulence—Paclitaxel—lung cancer	0.000143	0.00181	CcSEcCtD
Ruxolitinib—Nervous system disorder—Irinotecan—lung cancer	0.000143	0.0018	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Irinotecan—lung cancer	0.000143	0.0018	CcSEcCtD
Ruxolitinib—Haemoglobin—Docetaxel—lung cancer	0.000143	0.0018	CcSEcCtD
Ruxolitinib—Haemorrhage—Docetaxel—lung cancer	0.000142	0.00179	CcSEcCtD
Ruxolitinib—Infection—Gemcitabine—lung cancer	0.000141	0.00178	CcSEcCtD
Ruxolitinib—Dizziness—Vinblastine—lung cancer	0.000141	0.00177	CcSEcCtD
Ruxolitinib—Body temperature increased—Vinorelbine—lung cancer	0.00014	0.00176	CcSEcCtD
Ruxolitinib—Nervous system disorder—Gemcitabine—lung cancer	0.000139	0.00175	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Gemcitabine—lung cancer	0.000139	0.00175	CcSEcCtD
Ruxolitinib—Skin disorder—Gemcitabine—lung cancer	0.000138	0.00174	CcSEcCtD
Ruxolitinib—Anaemia—Etoposide—lung cancer	0.000137	0.00173	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—lung cancer	0.000137	0.00173	CcSEcCtD
Ruxolitinib—Dizziness—Topotecan—lung cancer	0.000137	0.00172	CcSEcCtD
Ruxolitinib—Dizziness—Erlotinib—lung cancer	0.000135	0.0017	CcSEcCtD
Ruxolitinib—Anaemia—Paclitaxel—lung cancer	0.000135	0.0017	CcSEcCtD
Ruxolitinib—Headache—Vinblastine—lung cancer	0.000133	0.00168	CcSEcCtD
Ruxolitinib—CAMK2G—Azacitidine—Gemcitabine—lung cancer	0.000132	0.0388	CbGdCrCtD
Ruxolitinib—Infection—Cisplatin—lung cancer	0.000131	0.00166	CcSEcCtD
Ruxolitinib—Nervous system disorder—Cisplatin—lung cancer	0.00013	0.00163	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Cisplatin—lung cancer	0.00013	0.00163	CcSEcCtD
Ruxolitinib—Headache—Topotecan—lung cancer	0.000129	0.00163	CcSEcCtD
Ruxolitinib—Skin disorder—Cisplatin—lung cancer	0.000129	0.00162	CcSEcCtD
Ruxolitinib—Headache—Erlotinib—lung cancer	0.000128	0.00161	CcSEcCtD
Ruxolitinib—Gastrointestinal haemorrhage—Doxorubicin—lung cancer	0.000128	0.00161	CcSEcCtD
Ruxolitinib—Asthenia—Vinorelbine—lung cancer	0.000127	0.0016	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Irinotecan—lung cancer	0.000126	0.00159	CcSEcCtD
Ruxolitinib—Fatigue—Irinotecan—lung cancer	0.000126	0.00158	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Etoposide—lung cancer	0.000126	0.00158	CcSEcCtD
Ruxolitinib—Pruritus—Vinorelbine—lung cancer	0.000125	0.00158	CcSEcCtD
Ruxolitinib—Malnutrition—Docetaxel—lung cancer	0.000123	0.00156	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—lung cancer	0.000123	0.00155	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Gemcitabine—lung cancer	0.000123	0.00154	CcSEcCtD
Ruxolitinib—Fatigue—Gemcitabine—lung cancer	0.000122	0.00154	CcSEcCtD
Ruxolitinib—Pancytopenia—Methotrexate—lung cancer	0.000121	0.00153	CcSEcCtD
Ruxolitinib—Infection—Etoposide—lung cancer	0.00012	0.00152	CcSEcCtD
Ruxolitinib—Neutropenia—Methotrexate—lung cancer	0.000119	0.0015	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Etoposide—lung cancer	0.000119	0.0015	CcSEcCtD
Ruxolitinib—Infection—Paclitaxel—lung cancer	0.000118	0.00149	CcSEcCtD
Ruxolitinib—Skin disorder—Etoposide—lung cancer	0.000118	0.00148	CcSEcCtD
Ruxolitinib—Dizziness—Vinorelbine—lung cancer	0.000117	0.00147	CcSEcCtD
Ruxolitinib—Nervous system disorder—Paclitaxel—lung cancer	0.000117	0.00147	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Paclitaxel—lung cancer	0.000116	0.00147	CcSEcCtD
Ruxolitinib—Skin disorder—Paclitaxel—lung cancer	0.000115	0.00145	CcSEcCtD
Ruxolitinib—Body temperature increased—Irinotecan—lung cancer	0.000115	0.00145	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Cisplatin—lung cancer	0.000114	0.00144	CcSEcCtD
Ruxolitinib—Anaemia—Docetaxel—lung cancer	0.000114	0.00144	CcSEcCtD
Ruxolitinib—Infestation NOS—Methotrexate—lung cancer	0.000114	0.00143	CcSEcCtD
Ruxolitinib—Infestation—Methotrexate—lung cancer	0.000114	0.00143	CcSEcCtD
Ruxolitinib—Alanine aminotransferase increased—Doxorubicin—lung cancer	0.000113	0.00142	CcSEcCtD
Ruxolitinib—Body temperature increased—Gemcitabine—lung cancer	0.000112	0.00141	CcSEcCtD
Ruxolitinib—Headache—Vinorelbine—lung cancer	0.000111	0.00139	CcSEcCtD
Ruxolitinib—Haematuria—Methotrexate—lung cancer	0.000109	0.00137	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Methotrexate—lung cancer	0.000108	0.00136	CcSEcCtD
Ruxolitinib—Epistaxis—Methotrexate—lung cancer	0.000107	0.00135	CcSEcCtD
Ruxolitinib—Pancytopenia—Doxorubicin—lung cancer	0.000105	0.00132	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Etoposide—lung cancer	0.000105	0.00132	CcSEcCtD
Ruxolitinib—Body temperature increased—Cisplatin—lung cancer	0.000105	0.00132	CcSEcCtD
Ruxolitinib—Asthenia—Irinotecan—lung cancer	0.000105	0.00132	CcSEcCtD
Ruxolitinib—Fatigue—Etoposide—lung cancer	0.000105	0.00132	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000104	0.00131	CcSEcCtD
Ruxolitinib—Neutropenia—Doxorubicin—lung cancer	0.000103	0.0013	CcSEcCtD
Ruxolitinib—Haemoglobin—Methotrexate—lung cancer	0.000103	0.00129	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000103	0.00129	CcSEcCtD
Ruxolitinib—Fatigue—Paclitaxel—lung cancer	0.000102	0.00129	CcSEcCtD
Ruxolitinib—Haemorrhage—Methotrexate—lung cancer	0.000102	0.00129	CcSEcCtD
Ruxolitinib—Asthenia—Gemcitabine—lung cancer	0.000102	0.00128	CcSEcCtD
Ruxolitinib—Weight increased—Doxorubicin—lung cancer	0.000101	0.00127	CcSEcCtD
Ruxolitinib—Pruritus—Gemcitabine—lung cancer	0.0001	0.00127	CcSEcCtD
Ruxolitinib—Infection—Docetaxel—lung cancer	0.0001	0.00126	CcSEcCtD
Ruxolitinib—Weight decreased—Doxorubicin—lung cancer	0.0001	0.00126	CcSEcCtD
Ruxolitinib—Nervous system disorder—Docetaxel—lung cancer	9.88e-05	0.00124	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Docetaxel—lung cancer	9.86e-05	0.00124	CcSEcCtD
Ruxolitinib—Infestation—Doxorubicin—lung cancer	9.86e-05	0.00124	CcSEcCtD
Ruxolitinib—Infestation NOS—Doxorubicin—lung cancer	9.86e-05	0.00124	CcSEcCtD
Ruxolitinib—Skin disorder—Docetaxel—lung cancer	9.78e-05	0.00123	CcSEcCtD
Ruxolitinib—Dizziness—Irinotecan—lung cancer	9.64e-05	0.00121	CcSEcCtD
Ruxolitinib—Body temperature increased—Etoposide—lung cancer	9.58e-05	0.00121	CcSEcCtD
Ruxolitinib—Urinary tract infection—Doxorubicin—lung cancer	9.58e-05	0.00121	CcSEcCtD
Ruxolitinib—Asthenia—Cisplatin—lung cancer	9.49e-05	0.0012	CcSEcCtD
Ruxolitinib—Haematuria—Doxorubicin—lung cancer	9.4e-05	0.00118	CcSEcCtD
Ruxolitinib—Body temperature increased—Paclitaxel—lung cancer	9.4e-05	0.00118	CcSEcCtD
Ruxolitinib—Hepatobiliary disease—Doxorubicin—lung cancer	9.32e-05	0.00117	CcSEcCtD
Ruxolitinib—Epistaxis—Doxorubicin—lung cancer	9.3e-05	0.00117	CcSEcCtD
Ruxolitinib—PLK1—Teniposide—Etoposide—lung cancer	9.25e-05	0.0273	CbGdCrCtD
Ruxolitinib—PLK4—Teniposide—Etoposide—lung cancer	9.25e-05	0.0273	CbGdCrCtD
Ruxolitinib—Headache—Irinotecan—lung cancer	9.13e-05	0.00115	CcSEcCtD
Ruxolitinib—Malnutrition—Methotrexate—lung cancer	8.9e-05	0.00112	CcSEcCtD
Ruxolitinib—Haemoglobin—Doxorubicin—lung cancer	8.89e-05	0.00112	CcSEcCtD
Ruxolitinib—Headache—Gemcitabine—lung cancer	8.89e-05	0.00112	CcSEcCtD
Ruxolitinib—Haemorrhage—Doxorubicin—lung cancer	8.85e-05	0.00112	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Docetaxel—lung cancer	8.7e-05	0.0011	CcSEcCtD
Ruxolitinib—Asthenia—Etoposide—lung cancer	8.7e-05	0.0011	CcSEcCtD
Ruxolitinib—Fatigue—Docetaxel—lung cancer	8.68e-05	0.00109	CcSEcCtD
Ruxolitinib—Pruritus—Etoposide—lung cancer	8.58e-05	0.00108	CcSEcCtD
Ruxolitinib—Asthenia—Paclitaxel—lung cancer	8.53e-05	0.00107	CcSEcCtD
Ruxolitinib—Pruritus—Paclitaxel—lung cancer	8.41e-05	0.00106	CcSEcCtD
Ruxolitinib—Anaemia—Methotrexate—lung cancer	8.22e-05	0.00104	CcSEcCtD
Ruxolitinib—Dizziness—Etoposide—lung cancer	8.02e-05	0.00101	CcSEcCtD
Ruxolitinib—Body temperature increased—Docetaxel—lung cancer	7.96e-05	0.001	CcSEcCtD
Ruxolitinib—Dizziness—Paclitaxel—lung cancer	7.86e-05	0.00099	CcSEcCtD
Ruxolitinib—Malnutrition—Doxorubicin—lung cancer	7.7e-05	0.000971	CcSEcCtD
Ruxolitinib—Headache—Etoposide—lung cancer	7.59e-05	0.000957	CcSEcCtD
Ruxolitinib—Flatulence—Doxorubicin—lung cancer	7.59e-05	0.000956	CcSEcCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	7.52e-05	0.000948	CcSEcCtD
Ruxolitinib—Headache—Paclitaxel—lung cancer	7.45e-05	0.000938	CcSEcCtD
Ruxolitinib—Asthenia—Docetaxel—lung cancer	7.23e-05	0.000911	CcSEcCtD
Ruxolitinib—Infection—Methotrexate—lung cancer	7.21e-05	0.000909	CcSEcCtD
Ruxolitinib—Pruritus—Docetaxel—lung cancer	7.13e-05	0.000898	CcSEcCtD
Ruxolitinib—Nervous system disorder—Methotrexate—lung cancer	7.12e-05	0.000897	CcSEcCtD
Ruxolitinib—Anaemia—Doxorubicin—lung cancer	7.12e-05	0.000897	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Methotrexate—lung cancer	7.11e-05	0.000896	CcSEcCtD
Ruxolitinib—Skin disorder—Methotrexate—lung cancer	7.05e-05	0.000889	CcSEcCtD
Ruxolitinib—Dizziness—Docetaxel—lung cancer	6.66e-05	0.000839	CcSEcCtD
Ruxolitinib—DYRK1A—Epirubicin—Doxorubicin—lung cancer	6.54e-05	0.0193	CbGdCrCtD
Ruxolitinib—DYRK1A—Idarubicin—Doxorubicin—lung cancer	6.54e-05	0.0193	CbGdCrCtD
Ruxolitinib—DYRK1A—Daunorubicin—Doxorubicin—lung cancer	6.54e-05	0.0193	CbGdCrCtD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	6.51e-05	0.000821	CcSEcCtD
Ruxolitinib—Headache—Docetaxel—lung cancer	6.31e-05	0.000795	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Methotrexate—lung cancer	6.27e-05	0.00079	CcSEcCtD
Ruxolitinib—Fatigue—Methotrexate—lung cancer	6.26e-05	0.000789	CcSEcCtD
Ruxolitinib—Infection—Doxorubicin—lung cancer	6.25e-05	0.000787	CcSEcCtD
Ruxolitinib—Nervous system disorder—Doxorubicin—lung cancer	6.17e-05	0.000777	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Doxorubicin—lung cancer	6.16e-05	0.000776	CcSEcCtD
Ruxolitinib—Skin disorder—Doxorubicin—lung cancer	6.11e-05	0.000769	CcSEcCtD
Ruxolitinib—Body temperature increased—Methotrexate—lung cancer	5.74e-05	0.000723	CcSEcCtD
Ruxolitinib—Gastrointestinal disorder—Doxorubicin—lung cancer	5.43e-05	0.000684	CcSEcCtD
Ruxolitinib—Fatigue—Doxorubicin—lung cancer	5.42e-05	0.000683	CcSEcCtD
Ruxolitinib—Asthenia—Methotrexate—lung cancer	5.21e-05	0.000656	CcSEcCtD
Ruxolitinib—PLK1—Cytarabine—Gemcitabine—lung cancer	5.21e-05	0.0154	CbGdCrCtD
Ruxolitinib—Pruritus—Methotrexate—lung cancer	5.14e-05	0.000647	CcSEcCtD
Ruxolitinib—Body temperature increased—Doxorubicin—lung cancer	4.97e-05	0.000626	CcSEcCtD
Ruxolitinib—Dizziness—Methotrexate—lung cancer	4.8e-05	0.000605	CcSEcCtD
Ruxolitinib—Headache—Methotrexate—lung cancer	4.55e-05	0.000573	CcSEcCtD
Ruxolitinib—Asthenia—Doxorubicin—lung cancer	4.51e-05	0.000568	CcSEcCtD
Ruxolitinib—PLK1—Idarubicin—Doxorubicin—lung cancer	4.47e-05	0.0132	CbGdCrCtD
Ruxolitinib—PLK4—Epirubicin—Doxorubicin—lung cancer	4.47e-05	0.0132	CbGdCrCtD
Ruxolitinib—PLK1—Epirubicin—Doxorubicin—lung cancer	4.47e-05	0.0132	CbGdCrCtD
Ruxolitinib—PLK4—Idarubicin—Doxorubicin—lung cancer	4.47e-05	0.0132	CbGdCrCtD
Ruxolitinib—PLK1—Daunorubicin—Doxorubicin—lung cancer	4.47e-05	0.0132	CbGdCrCtD
Ruxolitinib—Pruritus—Doxorubicin—lung cancer	4.45e-05	0.00056	CcSEcCtD
Ruxolitinib—Dizziness—Doxorubicin—lung cancer	4.16e-05	0.000524	CcSEcCtD
Ruxolitinib—Headache—Doxorubicin—lung cancer	3.94e-05	0.000496	CcSEcCtD
Ruxolitinib—IRAK1—Signaling Pathways—ERBB2—lung cancer	9.69e-07	6.26e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—AKT1—lung cancer	9.69e-07	6.25e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—VEGFA—lung cancer	9.65e-07	6.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—PIK3CA—lung cancer	9.58e-07	6.18e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—lung cancer	9.56e-07	6.17e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CB—lung cancer	9.56e-07	6.17e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—lung cancer	9.56e-07	6.17e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MDM2—lung cancer	9.54e-07	6.16e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NRAS—lung cancer	9.54e-07	6.16e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—KRAS—lung cancer	9.53e-07	6.15e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MYC—lung cancer	9.52e-07	6.15e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—RAF1—lung cancer	9.51e-07	6.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CDKN1A—lung cancer	9.43e-07	6.08e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—ERBB2—lung cancer	9.41e-07	6.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PTEN—lung cancer	9.4e-07	6.07e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—B4GALT5—lung cancer	9.36e-07	6.04e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—IL6—lung cancer	9.35e-07	6.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—lung cancer	9.31e-07	6.01e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—AKT1—lung cancer	9.31e-07	6.01e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MAPK3—lung cancer	9.29e-07	5.99e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—lung cancer	9.28e-07	5.99e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CB—lung cancer	9.28e-07	5.99e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MDM2—lung cancer	9.26e-07	5.97e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—KRAS—lung cancer	9.24e-07	5.97e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—RAF1—lung cancer	9.22e-07	5.95e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CXCL8—lung cancer	9.19e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CG—lung cancer	9.18e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KIT—lung cancer	9.18e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—APC—lung cancer	9.18e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—NRAS—lung cancer	9.18e-07	5.93e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MAPK3—lung cancer	9.13e-07	5.9e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—ERBB2—lung cancer	9.13e-07	5.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA4—lung cancer	9.1e-07	5.88e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGF—lung cancer	9.08e-07	5.86e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MYC—lung cancer	9.03e-07	5.83e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—PIK3CA—lung cancer	9.02e-07	5.82e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CB—lung cancer	9.01e-07	5.81e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—lung cancer	9.01e-07	5.81e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EP300—lung cancer	8.97e-07	5.79e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—AKT1—lung cancer	8.94e-07	5.77e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CXCL8—lung cancer	8.92e-07	5.76e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—PIK3CA—lung cancer	8.91e-07	5.75e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MYC—lung cancer	8.88e-07	5.73e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA2—lung cancer	8.87e-07	5.73e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—HRAS—lung cancer	8.86e-07	5.72e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—lung cancer	8.83e-07	5.7e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—KRAS—lung cancer	8.8e-07	5.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—lung cancer	8.8e-07	5.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—MAPK3—lung cancer	8.79e-07	5.68e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL2—lung cancer	8.78e-07	5.67e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—PIK3CA—lung cancer	8.75e-07	5.65e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—POMC—lung cancer	8.74e-07	5.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—SRC—lung cancer	8.72e-07	5.63e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CDKN1A—lung cancer	8.7e-07	5.62e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—lung cancer	8.69e-07	5.61e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PTEN—lung cancer	8.68e-07	5.6e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CXCL8—lung cancer	8.65e-07	5.59e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—BRAF—lung cancer	8.63e-07	5.57e-06	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—AKT1—lung cancer	8.63e-07	5.57e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—lung cancer	8.62e-07	5.57e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CCND1—lung cancer	8.56e-07	5.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTA1—lung cancer	8.56e-07	5.53e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—JUN—lung cancer	8.54e-07	5.52e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—lung cancer	8.54e-07	5.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6R—lung cancer	8.53e-07	5.5e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL2—lung cancer	8.53e-07	5.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CREBBP—lung cancer	8.51e-07	5.5e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—PIK3CA—lung cancer	8.49e-07	5.48e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—IL6—lung cancer	8.48e-07	5.48e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCC3—lung cancer	8.46e-07	5.46e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—lung cancer	8.41e-07	5.43e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—NRAS—lung cancer	8.39e-07	5.42e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—lung cancer	8.37e-07	5.4e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—KRAS—lung cancer	8.35e-07	5.39e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HRAS—lung cancer	8.34e-07	5.39e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MMP9—lung cancer	8.31e-07	5.37e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CCND1—lung cancer	8.31e-07	5.37e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—JUN—lung cancer	8.3e-07	5.35e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CDKN1A—lung cancer	8.28e-07	5.35e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—lung cancer	8.28e-07	5.35e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EP300—lung cancer	8.28e-07	5.35e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL2—lung cancer	8.27e-07	5.34e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PTEN—lung cancer	8.26e-07	5.33e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HRAS—lung cancer	8.25e-07	5.32e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—KRAS—lung cancer	8.21e-07	5.3e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKR1C1—lung cancer	8.2e-07	5.29e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAP2K1—lung cancer	8.13e-07	5.25e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HRAS—lung cancer	8.1e-07	5.23e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—PIK3CA—lung cancer	8.08e-07	5.22e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CD—lung cancer	8.07e-07	5.21e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MMP9—lung cancer	8.07e-07	5.21e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CCND1—lung cancer	8.06e-07	5.2e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—SRC—lung cancer	8.05e-07	5.2e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—JUN—lung cancer	8.05e-07	5.19e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CDKN1A—lung cancer	8.04e-07	5.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MAPK3—lung cancer	8.04e-07	5.19e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PTEN—lung cancer	8.02e-07	5.18e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—PIK3CA—lung cancer	8e-07	5.16e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—IL6—lung cancer	7.99e-07	5.15e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—UGT1A1—lung cancer	7.96e-07	5.14e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—KRAS—lung cancer	7.9e-07	5.1e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—IL6—lung cancer	7.89e-07	5.09e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EP300—lung cancer	7.88e-07	5.09e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HRAS—lung cancer	7.86e-07	5.07e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MMP9—lung cancer	7.83e-07	5.05e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—AKT1—lung cancer	7.83e-07	5.05e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CDKN1A—lung cancer	7.8e-07	5.03e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PTEN—lung cancer	7.78e-07	5.02e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—lung cancer	7.77e-07	5.01e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—IL6—lung cancer	7.75e-07	5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NRAS—lung cancer	7.75e-07	5e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GNG11—lung cancer	7.67e-07	4.95e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—PIK3CA—lung cancer	7.67e-07	4.95e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—SRC—lung cancer	7.66e-07	4.95e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EP300—lung cancer	7.65e-07	4.94e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—lung cancer	7.64e-07	4.93e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—PIK3CA—lung cancer	7.54e-07	4.87e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—IL6—lung cancer	7.52e-07	4.85e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HRAS—lung cancer	7.48e-07	4.83e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—VEGFA—lung cancer	7.46e-07	4.82e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—SRC—lung cancer	7.44e-07	4.8e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EP300—lung cancer	7.42e-07	4.79e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MAPK3—lung cancer	7.42e-07	4.79e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—lung cancer	7.42e-07	4.79e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—lung cancer	7.39e-07	4.77e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NRAS—lung cancer	7.37e-07	4.76e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—AKT1—lung cancer	7.37e-07	4.76e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALDOA—lung cancer	7.31e-07	4.72e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—lung cancer	7.3e-07	4.71e-06	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—AKT1—lung cancer	7.28e-07	4.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—PIK3CA—lung cancer	7.26e-07	4.69e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—VEGFA—lung cancer	7.25e-07	4.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MDM2—lung cancer	7.23e-07	4.67e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—KRAS—lung cancer	7.22e-07	4.66e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—SRC—lung cancer	7.22e-07	4.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MYC—lung cancer	7.22e-07	4.66e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—RAF1—lung cancer	7.21e-07	4.65e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—lung cancer	7.18e-07	4.63e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NRAS—lung cancer	7.16e-07	4.62e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—IL6—lung cancer	7.16e-07	4.62e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—AKT1—lung cancer	7.15e-07	4.62e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—ERBB2—lung cancer	7.13e-07	4.6e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HRAS—lung cancer	7.09e-07	4.58e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NCOA3—lung cancer	7.09e-07	4.58e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MAPK3—lung cancer	7.06e-07	4.56e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—lung cancer	7.06e-07	4.56e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—lung cancer	7.04e-07	4.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CB—lung cancer	7.04e-07	4.54e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—VEGFA—lung cancer	7.03e-07	4.54e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HRAS—lung cancer	6.98e-07	4.5e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—lung cancer	6.96e-07	4.49e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NRAS—lung cancer	6.94e-07	4.48e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—AKT1—lung cancer	6.94e-07	4.48e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCG2—lung cancer	6.9e-07	4.45e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ADCY1—lung cancer	6.9e-07	4.45e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MYC—lung cancer	6.87e-07	4.43e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MAPK3—lung cancer	6.86e-07	4.43e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—IL6—lung cancer	6.79e-07	4.38e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO2—lung cancer	6.77e-07	4.37e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—HPGDS—lung cancer	6.77e-07	4.37e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CXCL8—lung cancer	6.76e-07	4.36e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PPP2R1B—lung cancer	6.72e-07	4.34e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—HRAS—lung cancer	6.72e-07	4.34e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—lung cancer	6.72e-07	4.34e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—IL6—lung cancer	6.68e-07	4.31e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MYC—lung cancer	6.67e-07	4.3e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—KRAS—lung cancer	6.67e-07	4.3e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MAPK3—lung cancer	6.65e-07	4.29e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—PIK3CA—lung cancer	6.63e-07	4.28e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—AKT1—lung cancer	6.6e-07	4.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTT1—lung cancer	6.56e-07	4.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—GPCR downstream signaling—AKT1—lung cancer	6.53e-07	4.22e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—lung cancer	6.52e-07	4.21e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GCLC—lung cancer	6.49e-07	4.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2A6—lung cancer	6.49e-07	4.19e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—lung cancer	6.47e-07	4.18e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MYC—lung cancer	6.47e-07	4.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL2—lung cancer	6.46e-07	4.17e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—IL6—lung cancer	6.43e-07	4.15e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—KRAS—lung cancer	6.35e-07	4.1e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—lung cancer	6.33e-07	4.08e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CCND1—lung cancer	6.3e-07	4.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—JUN—lung cancer	6.29e-07	4.06e-06	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—AKT1—lung cancer	6.26e-07	4.04e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—KRAS—lung cancer	6.16e-07	3.98e-06	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—AKT1—lung cancer	6.16e-07	3.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ENO1—lung cancer	6.15e-07	3.97e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HRAS—lung cancer	6.14e-07	3.96e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—PIK3CA—lung cancer	6.13e-07	3.95e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MMP9—lung cancer	6.12e-07	3.95e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CDKN1A—lung cancer	6.09e-07	3.93e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PTEN—lung cancer	6.08e-07	3.92e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—KRAS—lung cancer	5.98e-07	3.86e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—AKT1—lung cancer	5.93e-07	3.83e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—IL6—lung cancer	5.88e-07	3.79e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—PIK3CA—lung cancer	5.83e-07	3.76e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EP300—lung cancer	5.8e-07	3.74e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HRAS—lung cancer	5.67e-07	3.66e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—PIK3CA—lung cancer	5.66e-07	3.65e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—lung cancer	5.64e-07	3.64e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—SRC—lung cancer	5.64e-07	3.64e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP2E1—lung cancer	5.52e-07	3.56e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—VEGFA—lung cancer	5.49e-07	3.55e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—PIK3CA—lung cancer	5.49e-07	3.54e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—lung cancer	5.48e-07	3.53e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—NQO1—lung cancer	5.45e-07	3.52e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—lung cancer	5.44e-07	3.51e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NRAS—lung cancer	5.42e-07	3.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—IL6—lung cancer	5.42e-07	3.5e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—AKT1—lung cancer	5.42e-07	3.5e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HRAS—lung cancer	5.39e-07	3.48e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—lung cancer	5.31e-07	3.43e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HRAS—lung cancer	5.24e-07	3.38e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MAPK3—lung cancer	5.2e-07	3.35e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—IL6—lung cancer	5.16e-07	3.33e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HRAS—lung cancer	5.08e-07	3.28e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MYC—lung cancer	5.05e-07	3.26e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—IL6—lung cancer	5.01e-07	3.24e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—AKT1—lung cancer	5e-07	3.23e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—lung cancer	4.94e-07	3.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—STK11—lung cancer	4.92e-07	3.17e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—IL6—lung cancer	4.86e-07	3.14e-06	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—AKT1—lung cancer	4.76e-07	3.07e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—KRAS—lung cancer	4.67e-07	3.01e-06	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—AKT1—lung cancer	4.62e-07	2.98e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTP1—lung cancer	4.55e-07	2.94e-06	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—AKT1—lung cancer	4.48e-07	2.89e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CAT—lung cancer	4.43e-07	2.86e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ABCB1—lung cancer	4.31e-07	2.78e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—PIK3CA—lung cancer	4.29e-07	2.77e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—TYMS—lung cancer	4.23e-07	2.73e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—GSTM1—lung cancer	4.18e-07	2.7e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—lung cancer	4.15e-07	2.68e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HRAS—lung cancer	3.97e-07	2.56e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CYP1A1—lung cancer	3.96e-07	2.56e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ERCC2—lung cancer	3.93e-07	2.54e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—IL6—lung cancer	3.8e-07	2.45e-06	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKT1—lung cancer	3.5e-07	2.26e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—APOA1—lung cancer	3.4e-07	2.19e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CG—lung cancer	3.1e-07	2e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—POMC—lung cancer	2.95e-07	1.91e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CREBBP—lung cancer	2.88e-07	1.86e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CD—lung cancer	2.73e-07	1.76e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—ALB—lung cancer	2.69e-07	1.74e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CB—lung cancer	2.38e-07	1.54e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTGS2—lung cancer	2.36e-07	1.52e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PTEN—lung cancer	2.06e-07	1.33e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—EP300—lung cancer	1.96e-07	1.27e-06	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—PIK3CA—lung cancer	1.45e-07	9.36e-07	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—AKT1—lung cancer	1.18e-07	7.65e-07	CbGpPWpGaD
